| Type | Title | Author(s) | Year | Views |
| Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models | Ma, BBY; Lui, VWY; Hui, CWC; Lau, CPY; Wong, CH; Hui, EP; Ng, MHL; Cheng, SH; Tsao, SW; Tsang, C-M; Cheung, CSF; Ho, K; Chan, ATC | 2014 | 55 |
| |
| Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell linesJournal:Investigational New Drugs | Ma, BBY; Lui, VWY; Cheung, CS; Lau, CPY; Ho, K; Hui, EP; Tsui, SKW; Ng, MH; Cheng, SH; Ng, PKS; Tsao, SW; Chan, ATC | 2013 | 66 |
| |
| Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinomaJournal:Cancer Chemotherapy and Pharmacology | Chan, SL; Wong, C-H; Lau, CPY; Zhou, Q; Hui, CWC; Lui, VWY; Ma, BBY; Chan, ATC; Yeo, W | 2013 | 46 |
| |
| Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell linesJournal:Investigational New Drugs | Ma, BBY; Lui, VWY; Hui, CWC; Lau, CPY; Wong, C-H; Hui, EP; Ng, MH; Tsao, SW; Li, Y; Chan, ATC | 2013 | 56 |
| |
| Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinomaJournal:Investigational New Drugs | Hui, EP; Lui, VWY; Wong, CSC; Ma, BBY; Lau, CPY; Cheung, CSF; Ho, K; Cheng, S-H; Ng, MHL; Chan, ATC | 2011 | 49 |
| |
| The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell linesJournal:Investigational New Drugs Publisher:Springer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-6997 | Ma, BBY; Lui, VWY; Hui, EP; Lau, CPY; Ho, K; Ng, MHL; Cheng, SH; Tsao, SW; Chan, ATC | 2010 | 391 |
| |
| The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell linesJournal:Investigational New Drugs | Ma, BBY; Sung, F; Tao, Q; Poon, FF; Lui, VW; Yeo, W; Chan, SL; Chan, ATC | 2010 | 44 |
| |
| Erratum: Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response (Investigational New Drugs DOI: 10.1007/s10637-009-9316-7)Journal:Investigational New Drugs Publisher:Springer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-6997 | Ma, BBY; Lui, VWY; Poon, FF; Wong, SCC; To, KF; Wong, E; Chen, H; Lo, KW; Tao, Q; Ng, MHL; Cheng, SH; Chan, ATC | 2010 | 566 |
| |
| Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of responseJournal:Investigational New Drugs Publisher:Springer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-6997 | Ma, BBY; Lui, VWY; Poon, FF; Wong, SCC; To, KF; Wong, E; Chen, H; Lo, KW; Tao, Q; Chan, ATC | 2010 | 593 |
| |
| STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitroJournal:International Journal of Cancer Publisher:John Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home | Lui, VWY; Wong, EYL; Ho, Y; Hong, B; Wong, SCC; Tao, Q; Choi, GCG; Au, TCC; Ho, K; Yau, DMS; Ma, BBY; Hui, EP; Chan, ASK; Tsang, CM; Tsao, SW; Grandis, JR; Chan, ATC | 2009 | 335 |
| |
| Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomasPublisher:Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc | Jin, H; Wang, X; Ying, J; Wong, AHY; Li, H; Lee, KY; Srivastava, G; Chan, ATC; Yeo, W; Ma, BBY; Putti, TC; Lung, ML; Shen, ZY; Xu, LY; Langford, C; Tao, Q | 2007 | 191 |
| |
| Pharmacoproteomics study of cetuximab in nasopharyngeal carcinomaJournal:Journal of Proteome Research Publisher:American Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/jprobs | Sung, FL; Pang, RTK; Ma, BBY; Lee, MML; Shuk, MC; Poon, TCW; Chan, ATC | 2006 | 61 |
| |
